Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of BRAF/NRAS Status
Fan Zhang, Lola Boutin, Ishani Das, Jeroen Melief, Madhurendra Singh, Marina Stantic, Lu Zhang, Mohammad Alzrigat, Alireza Azimi, Lucas Baldran-Groves, Wesam Bazzar, Michelle S. Libério, Jacob Goodwin, Rainer Tuominen, Veronica Höiom, , Lars‐Gunnar Larsson
This study shows that combining palbociclib and crizotinib enhances senescence and immune recognition in melanoma cells regardless of BRAF/NRAS status, reducing tumor growth.
bioRxiv · Jul 4, 2025 · PreprintCancer Biology